Healthcare

The stock price was in the spotlight after its share price recorded a significant jump. The Clayton-based pathology group lifted underlying EBIT 1.7% to $69.2 million and expanded its underlying EBITMarginby 20 basis points to 9.4%. Underlying net profit rose 4.3% to $35.5 million.

Two ASX-listed healthcare companies recorded sizeable share-price gains on 17 August 2026 as investors responded to developments in their respective clinical programs.Argenica Therapeutics (ASX:AGN)was up 17.65% to A$0.20, whileMesoblast (ASX:MSB)gained 9.05% to A$2.41, at the time of writing on 17 August 2026. Both companies …

Argenica Therapeutics Limited (ASX:AGN) was trading atA$0.20, up 17.65%, or A$0.03, at 2:02pm on 17 August 2026. The move follows the company’s 24 July quarterly activities andCash Flowupdate, which outlined progress toward a late-stage clinical trial for ARG-007, now known by the International Nonproprietary …

Mesoblast Limited (ASX:MSB) was trading atA$2.41, up 9.05%, or A$0.20, at 2:58pm on 17 August 2026. The share-price movement came on the same day the company announced completion of patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain …

Microba Life Sciences (ASX:MAP) has gained 10.42% as the company puts more emphasis on commercial diagnostics and cash discipline. July brought a multi-year agreement with SYNLAB, expanding the reach of Microba’s microbiome testing capabilities, while a June funding package was explicitly framed around delivering …

What has changed is the setup. Over the past few months the Perth-based neuroprotection developer has quietly cleared the regulatory obstacles that stalled its lead asset in the United States, secured an international generic name for the drug, and told the market it intends …

Australian Clinical Labs (ASX:ACL) has jumped 20.85% as the pathology group moves toward a newLeadershipphase and its FY26 results. The first-half numbers showed that revenue pressure did not preventEarningsimprovement, with operational efficiency, network optimisation and technologyInvestmentsupporting margins. The next stage will be shaped by …